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INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malig-
nancy and represents the sixth most commonly diagnosed cancer 
among women in the developed world.1 A lack of effective thera-
peutic options, coupled with the highly heterogeneous nature of 
EOC, and being typically diagnosed at an advanced metastatic 
stage, contribute to the lethality of EOC.2,3 Current therapeutic 
strategies involve exhaustive cytoreductive surgery and postop-
erative platinum- and taxane-based chemotherapy.4–6 However, 
effective treatment is complicated by the manifestation of EOC as 
multiple histotypes, which are differentially responsive to plati-
num- and  taxane-based combination chemotherapy treatments.7 
Furthermore, patients that initially respond well to platinum therapy 
almost inevitably relapse with chemo-resistant disease resulting in 
reduced overall survival. Thus, there is a critical need for targeted 
and durable therapeutic alternatives beyond the standard first-line 
chemotherapeutic agents.8–10
Oncolytic virotherapy promotes selective viral infection and lysing 
of cancer cells. The specific nature of oncolytic virus therapy stems 
from the selection of non- or low-pathogenic nonhuman viruses that 
display tropism for cancer-associated genetic mutations or aberrant 
signaling.11 Myxoma virus (MYXV) is a European rabbit-specific poxvi-
rus that has not been shown to cause disease in humans and is used as 
a pesticide to control Australian rabbit  populations.12 MYXV displays 
tropism for cancer cells with upregulation in active AKT signaling and 
dysfunctional p53, which is found in essentially all high-grade EOC.13 
Conversely, vvDD is an engineered poxvirus with deleted vaccinia 
growth factor and viral thymidine kinase genes, which limit its infec-
tion to cells harboring upregulated EGFR/RAS signaling commonly 
observed in low-grade EOCs.14 Point mutations in the strain of MRBV 
used in this study modify the matrix protein (M) and glycoprotein (G) 
effectively boosting its  replicative capacity in cancer cells while ren-
dering it unable to counteract an antiviral type I interferon response 
in healthy cells. Though its specific tropism for cancer cells is relatively 
undefined, MRBV has been shown to have potent oncolytic effects in 
a broad range of cancer cells, including EOC.15
The mode of EOC metastasis is unique among most solid 
malignancies, and therefore it likely possesses distinct and novel 
 mechanisms. EOC metastasis occurs via the shedding of malig-
nant cells from the primary tumor into the peritoneal cavity; this 
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Epithelial ovarian cancer is unique among most carcinomas in that metastasis occurs by direct dissemination of malignant cells 
traversing throughout the intraperitoneal fluid. Accordingly, we test new therapeutic strategies using an in vitro three-dimensional 
spheroid suspension culture model that mimics key steps of this metastatic process. In the present study, we sought to uncover 
the differential oncolytic efficacy among three different viruses—Myxoma virus, double-deleted vaccinia virus, and Maraba  
virus—using three ovarian cancer cell lines in our metastasis model system. Herein, we demonstrate that Maraba virus effectively 
infects, replicates, and kills epithelial ovarian cancer (EOC) cells in proliferating adherent cells and with slightly slower kinetics in 
tumor spheroids. Myxoma virus and vaccinia viruses infect and kill adherent cells to a much lesser extent than Maraba virus, and 
their oncolytic potential is almost completely attenuated in spheroids. Myxoma virus and vaccinia are able to infect and spread 
throughout spheroids, but are blocked in the final stages of the lytic cycle, and oncolytic-mediated cell killing is reactivated upon 
spheroid reattachment. Alternatively, Maraba virus has a remarkably reduced ability to initially enter spheroid cells, yet rapidly 
infects and spreads throughout spheroids generating significant cell killing effects. We show that low-density lipoprotein recep-
tor expression in ovarian cancer spheroids is reduced and this controls efficient Maraba virus binding and entry into infected cells. 
Taken together, these results are the first to implicate the potential impact of differential viral oncolytic properties at key steps of 
ovarian cancer metastasis.
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can occur in the context of ascites, an exudative fluid commonly 
associated with advanced-stage disease. Single cells in suspension 
within the ascites are susceptible to death through anoikis; thus 
aggregation of single cells into multicellular spheroids facilitates 
escape from cell death.16,17 Furthermore, EOC spheroid survival 
is maintained in the low-nutrient environment of the ascites by 
undergoing cellular quiescence and autophagy.18,19 This tumor cell 
dormancy phenotype within spheroids is thought to allow persis-
tence of microscopic EOC secondary deposits after treatment with 
first-line chemotherapeutics and support growth under more favor-
able conditions.20 In addition, spheroids have an enhanced capacity 
to attach and invade mesothelial-lined surfaces in the peritoneal 
space promoting the formation of secondary tumor nodules.16
We postulate that in the context of metastatic ovarian cancer, the 
ability to kill dormant tumor cells is essential to eradicate the poten-
tial for disease recurrence. In this study, we compare three oncolytic 
viruses, MYXV, vvDD and MRBV, in an in vitro spheroid culture model 
of ovarian cancer metastasis to determine whether they have the 
potential to kill dormant tumor cells residing in spheroids.
ReSUlTS
Oncolytic effects of MYXV, vvDD, and MRBV in ovarian cancer cell 
lines
To begin to define the optimal oncolytic viral approach to the eradi-
cation of dormant EOC cells in spheroids, we applied three differ-
ent viruses in an in vitro three-dimensional spheroid culture system, 
which we have established to model metastatic EOC (Figure 1). 
Distinct molecular characteristics typify the lifecycle of metastatic 
ovarian cancer cells as they move from a proliferative state in the 
solid tumor to the resting state in ascites-suspended spheroids and 
finally when these structures attach to a secondary site and cells 
proliferate to form a metastatic lesion. Herein, we performed onco-
lytic infections using proliferating adherent EOC cell lines, spheroids 
cultured in suspension, and spheroid reattachment to tissue culture 
substratum to determine whether molecular and cellular changes 
at these specific steps would affect oncolytic virus cell killing effi-
cacy. We selected the established HEYA8, SKOV3 and OVCAR8 
cell lines since they have been well-characterized genomically 
(Supplementary Table S1) and have been predicted to represent dif-
ferent EOC subtypes based on this data.21
First, we performed parallel viral infections of adherent EOC cell 
lines with established spheroids in suspension (Figure 2a). Even in 
proliferating adherent cultures, we found that MYXV, vvDD, and 
MRBV were capable of inducing oncolysis of EOC lines with dif-
ferential killing capacities among the three viruses and across cell 
lines (Figure 2). MYXV displayed the least potent killing and was 
unable to induce significant oncolysis at less than a multiplic-
ity of infection (MOI) 1 in all cell lines (Figure 2b). vvDD exhibited 
oncolysis at similar concentrations as MYXV, but was able to induce 
greater loss of viability in comparison. Among the three EOC cell 
lines, OVCAR8 cells displayed greatest sensitivity to vvDD and MYXV 
infection whereas SKOV3 cells were most resistant in adherent 
culture infections. In a similar fashion, when tested using ovarian 
cancer patient  ascites-derived primary cultures, vvDD yielded bet-
ter oncolytic activity than MYXV in the majority of clinical samples 
(Supplementary Figure S1). Although both MYXV and vvDD were 
Figure 1  In vitro three-dimensional spheroid model system of ovarian cancer metastasis. (a) Ovarian cancer cells are grown as adherent proliferating 
monolayer cultures, and are transferred to Ultra-Low Attachment tissue culture plastic-ware where they naturally form multicellular aggregates, 
or spheroids, when in suspension culture. Spheroids are subsequently transferred back to standard tissue culture plastic to facilitate adhesion and 
growth of cells out of viable spheroids. (b) Phase contrast images of ovarian cancer cells in each of the culture conditions outlined in panel a. (c) Left: 
Phase contrast microscopic image of freshly-collected ovarian cancer patient ascites indicating the presence of spheroids in suspension. Right: Image 
representing ovarian tumor nodules implanted on the peritoneal wall of an ovarian cancer patient at the time of laparoscopic surgery.
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able to induce modest oncolysis of EOC cell lines in adherent  culture, 
infection-mediated cell killing was dramatically reduced in EOC 
spheroids for all cell lines tested (Figure 2c). vvDD was completely 
ineffective at inducing oncolysis of SKOV3 spheroids, but it did 
maintain some oncolytic activity in HEYA8 and OVCAR8 spheroids.
These findings using MYXV and vvDD were in stark contrast to 
results of MRBV infection, which induced robust oncolysis- mediated 
cell killing across all EOC cell lines in adherent culture even at an MOI 
of 0.001 (Figure 2b). In contrast, MRBV infection of heterogeneous 
patient-derived cells yielded highly variable oncolytic effects with one 
sample exhibiting robust MRBV-mediated loss in cell viability similar 
to established EOC cell lines (Supplementary Figure S1). However, a 
potent oncolytic effect was observed in MRBV-infected HEYA8 and 
SKOV3 spheroids where dramatic loss of cellular viability was evident 
with as little as MOI 0.01 at three days postinfection. Interestingly, we 
observed a significant reduction in MRBV oncolytic effects in OVCAR8 
spheroids compared with adherent cells  suggesting that EOC cells 
may have the capacity to acquire resistance against MRBV infection 
in three-dimensional spheroid form (Figure 2c).
MRBV is significantly faster at inducing oncolysis of EOC cells
We hypothesized that the potent oncolysis of EOC cells by MRBV 
may be due to a rapid ability to replicate its small RNA-based 
genome, allowing it to complete multiple rounds of infection within 
the experimental time frame of 72 hours. MRBV contrasts the large 
poxviruses, MYXV and vvDD, which have been shown to take up to 
several days to complete their life cycle, thus they may only com-
plete a single round of infection within 72 hours.
To assess this directly in our system, we sought to compare viral 
infection kinetics among MYXV, vvDD, and MRBV in both adherent 
and spheroid cultures. Cells were infected with an MOI 10 to maxi-
mize infection of all cells at the initial time point. We then assayed cell 
viability as an initial surrogate to observe virus infection over 5 days. In 
adherent culture, we found that MRBV was able to induce oncolysis in 
both HEYA8 and OVCAR8 cells within 24 hours of infection (Figure 3a). 
In support of our previous findings (Figure 2b), MRBV exhibited a 
significant delay of infection in adherent SKOV3 cells taking over 48 
hours to die from MRBV infection. In contrast, complete oncolysis of 
adherent EOC cells by MYXV and vvDD required up to 5 days.
Figure 2 Analysis of MYXV, vvDD, and MRBV oncolytic-mediated killing of EOC cell lines in adherent and spheroid culture. (a) Schematic representation 
of viral infection of ovarian cancer cells in adherent and spheroid culture. (b) HEYA8, SKOV3, and OVCAR8 cells were infected at increasing concentrations 
to a maximum of multiplicity of infection (MOI) 10, as indicated; UV-inactivated virus was used at a MOI of 10. Cell viability was measured after 72 hours 
using CellTiter-Glo. (c) HEYA8, SKOV3, and OVCAR8 cells were seeded to Ultra-Low Attachment dishes to form spheroids over 3 days, then infected at 
the indicated doses; spheroid cell viability was assayed as in panel b (*P < 0.05). EOC, epithelial ovarian cancer; MYXV, Myxoma virus.
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We have previously shown that MYXV replication is attenuated 
in EOC spheroids compared to infection of adherent monolayer 
cells.22 Therefore, we tested the kinetics of MYXV, vvDD, and 
MRBV infection in spheroids to compare directly with our results 
using proliferating adherent cell lines. We found that MYXV was 
largely ineffective at inducing detectable oncolysis in EOC spher-
oids by three days, but cell viability was reduced in HEYA8 and 
OVCAR8 spheroids by 5 days postinfection (Figure 3b). Although 
a 72-hour infection of EOC spheroids with vvDD yielded little 
oncolysis, extending the time course to 5 days was sufficient for 
marked loss of HEYA8 and OVCAR8 spheroid cell viability. Time 
course infections with MRBV resulted in cell death between 48 
and 72 hours for both HEYA8 and SKOV3 spheroids. Interestingly, 
OVCAR8 spheroids were relatively resistant to MRBV-mediated 
cell killing with a limited extent of cell death similar to what 
we observed for vvDD. This significantly contrasts MRBV infec-
tions of adherent EOC cell lines, including OVCAR8 cells, which 
displayed significant cell death within 24 hours. These unex-
pected results reinforce the idea that the potential underlying 
mechanisms governing oncolytic efficacy in EOC cells may be 
quite dynamic, and stress the importance of preclinical testing in 
complementary in vitro model systems.
MRBV produces significantly more virus progeny than MYXV and 
vvDD
We postulated that the observed differences in oncolytic effect 
among the three viruses in our spheroid culture system were also 
impacted by the efficiency of total virus production. To assess this 
directly, we infected adherent cells and spheroids and titrated total 
infectious virus particles. MRBV infection of adherent EOC cell lines 
yielded significantly more infectious viral progeny compared to both 
vvDD (7- to 17-fold increase) and MYXV (90- to 400-fold increase) 
(Table 1). Moreover, the number of viral progeny produced from 
MRBV infection in adherent culture was relatively similar among the 
three EOC cell lines. In spheroids, however, infectious progeny pro-
duced by MRBV infection was more variable among cell lines. MRBV 
infection of SKOV3 spheroids yielded 16-fold less virus and OVCAR8 
spheroids yielded 69-fold less than HEYA8 spheroids (Table 1). These 
MRBV titers were congruent with our results of cell viability demon-
strating reduced MRBV oncolysis of OVCAR8 spheroids (Figure 2c). 
The number of viral progeny produced from vvDD infections was 
similarly reduced in spheroids among cell lines tested. In fact, both 
MYXV and vvDD were able to produce only a 0.2- to 3.2-fold increase 
in viral progeny than what was used to initiate infection. Again, this 
result suggests that EOC spheroids possess physical or molecular 
changes in cells that significantly impact the replicative life cycle or 
amplification for both MYXV and vvDD in these dynamic structures.
Table 1 Quantification of oncolytic virus production in 
infected adherent ovarian cancer cells and spheroids
 Adherent culturea
HEYA8 SKOV3 OVCAR8
MYXV 1.38 ± 0.08 × 105 5.37 ± 0.21 × 105 1.30 ± 0.13 × 105
vvDD 7.78 ± 1.22 × 106 2.78 ± 0.35 × 106 2.83 ± 0.59 × 106
MRBV 5.52 ± 1.55 × 107 4.82 ± 1.11 × 107 2.38 ± 0.43 × 107
Spheroid cultureb
HEYA8 SKOV3 OVCAR8
MYXV 8.54 ± 2.07 × 105 1.75 ± 0.33 × 105 1.12 ± 0.34 × 105
vvDD 1.60 ± 0.21 × 106 3.12 ± 1.58 × 105 6.04 ± 1.39 × 105
MRBV 1.09 ± 0.15 × 108 6.80 ± 0.78 × 106 1.58 ± 0.41 × 106
aIn adherent culture, 2.5 × 104 cells were infected in 24-well dishes at MOI 
10 (2.5 × 105 pfu). bIn spheroid culture, 5 × 104 cells were infected in 24-well 
Ultra-Low Attachment cluster plates at MOI 10 (5 × 105 pfu).
MOI, multiplicity of infection.
Figure 3 Rapid kinetics of MRBV-mediated killing of epithelial ovarian cancer (EOC) cells and spheroids compared with MYXV and vvDD. (a) MRBV-mediated 
cell killing is observed within 24 hours in adherent EOC cells, but requires longer incubation in SKOV3 cells. Oncolysis of adherent cells by MYXV and vvDD 
is considerably slower. (b) MRBV produces rapid cell killing in spheroids, but there is an incomplete oncolytic effect in SKOV3 and OVCAR8 spheroids. EOC 
spheroids have reduced viability due to vvDD infection by 5 days, yet remain relatively resistant to MYXV infection (*P < 0.05). MYXV, Myxoma virus.
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Activation of MYXV and vvDD oncolysis upon spheroid 
reattachment
We use spheroid reattachment as a general method to assess cell 
viability within these structures, as well as to model metastasis 
formation due to adhesion of spheroids to secondary sites. To this 
end, EOC spheroids were infected for 72 hours prior to transfer to 
adherent culture for spheroid reattachment (Figure 4a). Spheroid 
cells are allowed to reattach and disperse for another 72 hours, 
after which the dispersion area of cells from infected spheroids 
was quantified (Figure 4b). Despite lacking a significant oncolytic 
cell-killing effect in spheroids while in suspension, oncolysis medi-
ated by both MYXV and vvDD was activated upon spheroid reat-
tachment and significantly reduced the ability of cells to disperse 
from spheroids and form a viable monolayer (Figure 4c,d). Reduced 
dispersion was apparent within 24 hours after reattachment and 
sustained for up to 4 days (Supplementary Figure S2). Due to its dra-
matic impact on spheroid cell viability, MRBV infection completely 
prevented reattachment of HEYA8 and SKOV3 spheroids (Figure 4c 
and Supplementary Figure S2). Although our previous results of cell 
viability indicated a marginal effect of vvDD infection on OVCAR8 
spheroids (Figure 2c), vvDD completely prevented OVCAR8 spher-
oid reattachment suggesting a significant reduction of cell viability 
in these structures. Interestingly, and in marked contrast to vvDD, 
MRBV-infected OVCAR8 spheroid cells were still capable of reat-
taching and dispersing, but to a lesser extent than mock-infected 
 controls (Figure 4c,d and Supplementary Figure S2).
Figure 4 MYXV and vvDD oncolysis is reactivated after spheroid reattachment. (a) Schematic representation of spheroid infection followed by reattachment 
to standard tissue culture-treated plastic. (b) Representative image of dispersion area quantification as denoted by dashed outline. (c) HEYA8, SKOV3, and 
OVCAR8 cells were seeded to form spheroids then infected with MYXV, vvDD, or MRBV for 72 hours. Infected spheroids were transferred to adherent 
culture to allow reattachment for 72 hours, then fixed and stained. Spheroid reattachment was either completely absent (indicating lack of viable cells), 
or dispersion of cells from the attached spheroid was significantly reduced (indicating reactivation of oncolytic activity upon reattachment to adherent 
culture). Scale bar: 1 mm. (d) Quantification of mean dispersion area was performed using ImageJ software (*P < 0.05). MYXV, Myxoma virus.
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We next sought to examine the direct oncolytic effect of all three 
viruses on established reattached spheroids (Figure 5a). This facili-
tates our ability to evaluate their potential to target metastases, 
as well as determine whether insensitivity to oncolytic virus infec-
tion observed in suspension spheroids also existed in reattached 
spheroid nodules. We observed virus infection of attached spher-
oids with treatment of MYXV, vvDD, and MRBV within 24 hours 
using green fluorescent protein expression as a marker (Figure 5b); 
this resulted in cytopathic effect in the dispersing adherent cells 
emanating from attached spheroids while leaving the spheroid 
cores relatively intact (Figure 5c). These findings further emphasize 
the requirement of cells to be adherent to promote MYXV- and 
vvDD-induced oncolysis. Similar to reduced cytopathic efficacy 
observed in MRBV infection of OVCAR8 spheroids, we observed 
reduced green fluorescent protein expression in MRBV-infected 
OVCAR8 attached spheroids when compared with MRBV-infected 
HEYA8 and SKOV3 attached spheroids, suggesting decreased viral 
entry or replicative potential in OVCAR8 spheroids.
Figure 5 Reattached epithelial ovarian cancer (EOC) spheroids are susceptible to MRBV infection. (a) Schematic representation of the infection of 
reattached spheroids. (b) HEYA8, SKOV3, and OVCAR8 cells were seeded to form spheroids, transferred to adherent culture to attach and disperse for 
72 hours, and then infected with MYXV, vvDD, or MRBV. Bright field and fluorescence images were captured at 24 hours postinfection and images were 
merged using Adobe Photoshop software. (c) After 72 hours of infection, SKOV3 and HEYA8 spheroids and dispersing cells are completely eradicated 
by MRBV infection, yet OVCAR8 spheroids and dispersing cells exhibit less oncolytic-mediated cell death. Infection by vvDD is more effective to reduce 
viable cells than MYXV for all reattached spheroids. Scale bar: 1 mm. MYXV, Myxoma virus.
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MRBV entry into EOC spheroid cells is significantly reduced
Since we had observed an appreciable difference for MYXV and 
vvDD to induce oncolysis of spheroids, and slower infection kinet-
ics of spheroids by MRBV particularly in OVCAR8 spheroids, we 
sought to determine the efficiency of virus entry into adherent cells 
and spheroids. To achieve this end, we titrated both the amount of 
virus remaining in the supernatant and that which had entered the 
cell. Although we had observed a significant reduction in oncolytic 
efficacy in EOC spheroids for MYXV and vvDD (Figure 2b,c), there 
was no significant difference for either MYXV or vvDD to enter 
adherent or spheroids cells (Figure 6a). In contrast, we observed a 
significant reduction in the ability of MRBV to enter spheroids for all 
three EOC cell lines when compared with adherent cells.
MRBV binding and infection of EOC spheroids requires low-density 
lipoprotein receptor (LDLR) expression
To investigate the acquired mechanism determining the enhanced 
ability of MRBV to enter adherent EOC cells compared with spher-
oids, we postulated this was due to changes in the expression of 
a cell surface receptor required for MRBV entry. Previous studies 
have identified the LDLR as a cell surface receptor that is used by 
the closely-related vesicular stomatitis virus (VSV). Since the glyco-
protein responsible for binding and entry of host cells by VSV shares 
80% amino acid sequence homology with MRBV glycoprotein, we 
sought to determine if the mechanism of MRBV entry in EOC cells 
was LDLR mediated. Indeed, we observed a consistent decrease 
in the expression of LDLR protein expression in day-3 spheroids 
when compared with adherent cells among multiple EOC cell lines 
(Figure  6b). To test this mechanism further, we performed siRNA 
knockdown of LDLR to validate whether LDLR is required by MRBV to 
gain entry to host cells. LDLR knockdown in SKOV3 cells (Figure 6c) 
Table 2 Summary of overall results for MYXV, vvDD, and 
MRBV oncolytic efficacy in ovarian cancer adherent cells and 
spheroids
HEYA8 SKOV3 OVCAR8
ADH SPH ADH SPH ADH SPH
MYXV ++ − ++ − ++ −
vvDD ++ + ++ − ++ ++
MRBV ++++ +++ ++++ +++ ++++ +
ADH, adherent cells; MYXV, Myxoma virus; SPH, spheroids.
Figure 6 Efficient MRBV entry into ovarian cancer cells requires low-density lipoprotein receptor (LDLR) expression. (a) HEYA8, SKOV3, and OVCAR8 
cells were seeded to adherent and spheroid culture, and infected with MRBV, vvDD, and MYXV for 1 hour at 4 °C to allow adsorption. Virus titers from 
cell lysates are shown relative to total virus collected (i.e., supernatant + cells). MRBV titers were determined using supernatant only. Virus treatment in 
the absence of cells were used as controls. MRBV binding was significantly reduced in EOC spheroids for all three cell lines tested when compared with 
MYXV and vvDD. (b) LDLR protein expression is reduced in ovarian cancer day-3 spheroids as compared with proliferating adherent cells; this results was 
also observed in the HEY and OVCAR3 cell lines. (c) Western blot demonstrating siRNA-mediated LDLR knockdown performed by transient transfection 
of SKOV3 cells. (d) MRBV binding is reduced in SKOV3 cells with LDLR knockdown as compared with siNT control transfected cells. (e) LDLR knockdown 
significantly decreases MRBV-mediated oncolytic SKOV3 cell death as determined by CellTiter-Glo after 24 hours, whereas there is no effect on viability 
after MYXV and vvDD infection (*P < 0.05; **P < 0.01). EOC, epithelial ovarian cancer; MYXV, Myxoma virus.
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resulted in a significant decrease in MRBV entry (Figure 6d), and a 
resultant increase in cell viability in MRBV-infected cells as com-
pared with knockdown control SKOV3 cells (Figure 6e). In contrast, 
knockdown of LDLR had no effect on cell viability due to infection 
with MYXV or vvDD.
DISCUSSION
Most ovarian cancer patients are diagnosed with late-stage metastatic 
disease, are subjected to multiple successive recurrences, and will 
eventually succumb to chemotherapy-resistant disease. Thus, the first 
objective of this study was to test the potential of MYXV, vvDD, and 
MRBV as therapeutic alternatives to conventional chemotherapeutics 
for the treatment of metastatic EOC. A second important objective was 
to demonstrate that testing viral oncolytics in a uniquely different cul-
ture-based model system, i.e., three-dimensional spheroids, can elicit 
unforeseen results and uncover important mechanisms controlling 
virus infection and efficacy. MRBV is clearly the most potent oncolytic 
virus among the EOC cell lines that we tested in both proliferating 
adherent cells and quiescent 3D spheroids. However, we are the first 
to discover that endogenous downregulation of LDLR protein expres-
sion in spheroids has the potential to reduce MRBV oncolytic efficacy. 
Although the larger and slower poxviruses MYXV and vvDD were less 
infectious and produced less virus progeny in ovarian cancer cell lines 
and spheroids, virus-infected spheroids displayed reduced capacity 
to reattach and grow due to reactivation of virus infection. Given our 
results, we propose that early in vitro testing of viral oncolytic agents 
should consider using an experimentally-tractable cell culture system 
such as ours that mimics unique mechanisms of disease metastasis.
We observed significant differential effects of the three viruses 
among the three cell lines and when assessing the different steps of 
metastasis as modeled in our culture system, particularly when com-
paring adherent to spheroid cells (summarized in Table 2). In adher-
ent culture, MRBV clearly exhibited the highest oncolytic activity. 
Adherent monolayer cultures represent proliferating ovarian cancer 
cells with intact growth factor signaling. In contrast, overall efficacy 
was reduced among the three viruses in spheroids. In particular, the 
almost universal MRBV oncolytic efficacy was dramatically reduced 
in OVCAR8 spheroids. We demonstrate that one of the key recep-
tors MRBV utilizes to bind and enter ovarian cancer cells is LDLR; 
surprisingly, we also show that the LDLR receptor is downregulated 
in spheroids compared with adherent proliferating ovarian cancer 
cells. This could be related to the dormant phenotype and the fact 
that the overall anabolic metabolism is reduced in spheroids.18,19,23 It 
has been reported previously that densely-packed cells downregu-
late LDLR resulting in decreased cholesterol metabolism in gyneco-
logic cancer cell lines.24,25 It is possible that this same effect of LDLR 
downregulation is occurring in densely-packed cells comprising 
EOC spheroids thereby reducing initial virus entry. It is important 
to note, however, that after this initial delay in virus entry, MRBV is 
capable of infecting spheroid cells and producing infectious viral 
progeny albeit with slower kinetics compared with adherent prolif-
erating cells. We postulate that the dormant phenotype observed in 
cultured spheroids is analogous to microregions of tumors that are 
avascular or lack essential growth factor and nutrient availability. To 
that end, it would be important to address LDLR expression level in 
ovarian tumors directly, and assess whether modifications can be 
made to increase MRBV binding and entry to the potentially resis-
tant subpopulations due to altered metabolism.
MRBV is the most potent of the three oncolytic viruses tested. It 
exhibited the greatest killing in the three cell lines. It had the fast-
est kinetics and generated the most infectious progeny. This is 
most likely supported by the fact that MRBV is a rhabdovirus with 
a short life cycle and small genome. This has also been observed 
for MRBV in other cancer cell systems, and its related family mem-
bers, such as the most widely-studied rhabdovirus, VSV.15,26 MRBV 
was originally identified from a large biorepository of rhabdoviruses 
as having potent activity in several different cancer cell lines.15 This 
group also developed the double point mutant MRBV MG1, which 
exhibited enhanced growth in cancer cells and reduced effects in 
normal cells. MRBV is rapidly entering clinical trials with engineered 
vectors expressing tumor-associated antigens, such as MAGE M3.27 
We postulate that identifying similar tumor-associated antigens 
specific for ovarian cancer, perhaps other MAGE proteins,28 could 
be rapidly applied to develop clinically-useful MRBV oncolytic viral 
vectors. It has become increasingly evident that oncolytic virus effi-
cacy in vivo relies on eliciting an active immune response, which 
may lead to more durable antitumor effects in the long-term.29 We 
recognize that the cell culture-based system used in this report is 
unable to assess the contribution of the immune system; however, 
we argue that our in vitro ovarian cancer spheroid metastasis model 
is a useful, rapid and widely-amenable experimental tool for initial 
testing of novel oncolytic vectors across histologic and molecularly-
defined cancer subtypes, particularly using patient-derived malig-
nant tumor cells.
Generally speaking, ovarian cancer spheroids are more restrictive 
to viral oncolysis. One argument could be made regarding the gen-
eral physical structure of spheroid that may make them less read-
ily infected by viruses. Interestingly, we found that for MYXV and 
vvDD viruses there was no difference in binding of these viruses to 
adherent monolayer cultured cells compared with 3D spheroids in 
 suspension. However, the ability of these two different viruses to 
complete their lifecycle was dramatically restricted in spheroids. In 
this case, this is most likely due to the inherent phenotype of ovarian 
cancer cells in spheroids, namely downregulation of AKT signaling, 
induction of autophagy, and a cellular quiescent phenotype.18,19,23 
Oncolytic viruses typically rely on overactive or mutant growth fac-
tor signaling to promote their life cycle and this constitutes a critical 
cancer-specific tropism.30 We have shown in other reports that the 
AKT signaling pathway is markedly downregulated in ovarian cancer 
cell spheroids, and this directly affected MYXV oncolytic  efficacy.22 
Soares and colleagues have shown that increased levels of phos-
phorylated AKT are required for late-stage vvDD morphogenesis 
and production of virus progeny.31 Likewise, phosphorylated AKT is 
also required for permissive infection of MYXV; however, the specific 
stage of the requirement is currently undefined.32 In our previous 
study, we demonstrated that activated AKT levels are significantly 
reduced within spheroids as compared with adherent EOC cells, but 
this activity is reinstated upon spheroid reattachment.19 Our  present 
results are in agreement with this phenomenon, since reattach-
ment of spheroids triggered the reactivation of MYXV and vvDD- 
mediated oncolytic killing of dispersing cells.
MYXV and vvDD reach late-stage virus production in spheroids 
yet are restricted to cause cell death. This restriction is quickly 
relieved upon spheroid reattachment when the dormant-to-prolif-
erative switch” occurs19 and cells are again susceptible to viral-medi-
ated oncolytic cell death. This result is consistent with our previous 
study using MYXV in patient-derived spheroids.22 We use spheroid 
reattachment as a model of intraperitoneal metastatic seeding of 
malignant cells akin to what is observed in patients.16,17,33,34 In fact, 
OVCAR8-generated spheroids were dramatically susceptible to 
vvDD-induced cell death when using spheroid reattachment as 
an assay. It would be interesting to determine what mechanisms 
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are utilized by vvDD to affect OVCAR8 spheroid cells compared 
with MRBV, an agent that was largely ineffective only in OVCAR8 
spheroids. This knowledge may uncover novel strategies to engi-
neer MRBV to make it more widely applicable to ovarian tumors of 
different histologies and pathobiologies across the ovarian cancer 
patient spectrum. Given our results, we propose that tumor-homing 
oncolytic viruses could be potent therapeutic agents with particu-
larly high tropism and efficacy to seek and destroy these persistent 
microscopic structures in a patient after surgical debulking of mac-
roscopic disease.
MATeRIAlS AND MeTHODS
Cell culture
HEYA8, SKOV3, HEY, Vero, HeLa, and BGMK cell lines were cultured in 
Dulbecco’s Modified Eagle medium (Wisent) supplemented with 5% 
fetal bovine serum (Wisent). OVCAR8 and OVCAR3 cells were cultured in 
Dulbecco’s Modified Eagle medium/F12 (Wisent) containing 10% fetal 
bovine serum. All cell lines were cultured in a humidified environment at 37 
°C with 5% CO2.
Ascites fluid obtained from ovarian cancer patients at the time of 
de bulking surgery or paracentesis was used to generate primary cell cul-
tures as described previously.22 Cells were cultured in Dulbecco’s Modified 
Eagle medium/F12 supplemented with 10% fetal bovine serum and grown 
in a 37 °C humidified atmosphere of 95% air and 5% CO2. Since these rep-
resent primary cell cultures, all experiments were performed between pas-
sages 3 and 5. All patient-derived cells were used in accordance with institu-
tional human research ethics board approval (UWO HSREB 12668E).
Virus production
MYXV, vvDD, and MRBV were amplified in BGMK, HeLa, and Vero cell lines, 
respectively. BGMK cells were infected with MYXV at MOI 10 for 1 hour. After 
48 hours of infection, cells were harvested and lysed, cell debris was pelleted 
by centrifugation and supernatant with MYXV was purified.35 HeLa cells were 
infected with vvDD at MOI 0.1 and 60 hours after infection cells and virus 
were harvested and purified similar to MYXV. Vero cells were infected with 
MRBV at MOI 0.01. After 20 hours of infection, supernatant was collected 
and virus was purified using a 0.2 micron filter. All virus constructs have been 
engineered previously to express green fluorescent protein from endog-
enous viral promoters: MYXV,36,37 vvDD,14 MRBV.26 The MRBV MG1 mutant 
strain used in these experiments has been described previously.26
Viral titer quantification
Quantification of MYXV, vvDD, and MRBV titers were performed using BGMK, 
HeLa, and Vero cells, respectively. Virus titers were determined through limit-
ing dilutions of virus on BGMK, HeLa, or Vero. Agarose overlays and plaque 
assays were performed to determine virus concentration.
Adherent culture. HEYA8, SKOV3, and OVCAR8 cells were seeded at 25,000 
cells/well of a 24-well plate and infected with MYXV, vvDD, or MRBV at 
MOI 10. After 48 hours MRBV infection, and 4 days after MYXV and vvDD 
infection, cells and supernatant were harvested together for virus content. 
MYXV, vvDD, and MRBV were titrated on BGMK, HeLa, and Vero cell lines, 
respectively.
Spheroid culture. HEYA8, SKOV3, and OVCAR8 cells were seeded at 50,000 
cells/well of a 24-well Ultra-Low Attachment cluster plate and allowed to 
form spheroids for 3 days. Spheroids were then infected while in suspen-
sion with MYXV, vvDD, or MRBV at MOI 10. Seventy-two hours after MRBV 
infection, and 5 days after MYXV and vvDD infection, spheroids and super-
natant were harvested together for virus content. Spheroids were triturated 
using a 26-gauge needle and titered as described above.
Virus infection of EOC cells
HEYA8, SKOV3, and OVCAR8 were seeded at 5,000 cells/well of a 96-well 
plate and were infected the following day with MYXV, vvDD, or MRBV at a 
MOI 0.001, 0.01, 0.1, 1, and 10. The appropriate UV-inactivated virus at MOI 
10 or no virus (mock infected) was used as controls. Seventy-two hours 
postinfection, viability was assayed using CellTiter-Glo Luminescent Cell 
Viability Assay (Promega, Madison, WI).
For infection of EOC spheroids, cells were seeded at 50,000 cells/well of 
a 24-well Ultra-Low Attachment cluster plate (Corning, Corning, NY) and 
spheroids were allowed to form over 72 hours. Spheroids were then infected 
at MOI 0.01, 0.1, 1, and 10, using the same controls as described for adherent 
cell infections.
For infection of reattached spheroids, spheroids were formed as previ-
ously described, in the absence of virus, and transferred to six-well tissue 
culture-treated plates for reattachment. Forty-eight hours after reattach-
ment, spheroids were then infected at MOI 10 based on the initial seeding 
of 50,000 cells/well of a 24-well Ultra-Low Attachment plate. Spheroids were 
imaged 24 hours after infection then fixed and stained at 72 hours postin-
fection using HEMA3 (Fisher HealthCare, Ottawa, Ontario, Canada). Phase 
contrast and fluorescence images of infected cells and spheroids were cap-
tured during each experiment using a Leica DMI 4000B inverted microscope. 
Fluorescence and phase contrast overlays were generated using Adobe 
Photoshop.
Kinetics of infection and cell viability
HEYA8, SKOV3, and OVCAR8 cells were seeded as described above for both 
adherent and spheroid cultures. Cells were then infected with an MOI 10 to 
allow for maximum virus infection and achieve synchronous virus lifecycle 
among all cells within the culture. Viability was then assayed using CellTiter-
Glo at 12, 24, 36, 48, 72 hours, and 4 and 5 days after infection for adherent 
cultures and at 24 hours intervals for up to 6 days with spheroids. To assay 
cell viability in spheroids, spheroids were collected and pelleted, followed 
by resuspension in CellTiter-Glo and trituration with a 26-gauge needle. 
Luminescence was measured using a Wallac Plate Reader (PerkinElmer, 
Waltham, MA).
Spheroid reattachment quantification
Cells were seeded at 50,000 cells/well of a 24-well Ultra-Low Attachment 
cluster plate to form spheroids over 72 hours. Spheroids were infected with 
MYXV, vvDD, or MRBV at MOI 10. Spheroids were reattached by transferring 
to six-well tissue culture plates. Spheroids were permitted to attach and dis-
perse for an additional 72 hours prior to fixing and staining using HEMA3. 
Dispersion areas were calculated using ImageJ 1.48 software (NIH) by sub-
tracting the area of the core spheroid from the total area of the dispersion 
zone.
Virus entry quantification
Adherent cells and spheroids were infected with MOI 10 MYXV, vvDD, and 
MRBV for 1 hour at 4 °C to allow virus infection of cells, but to prevent virus 
uncoating that would affect subsequent quantification of infectious virus 
titers. After 1 hour of virus adsorption, supernatant and cells were separated 
and cell pellets were washed twice with PBS. Spheroids and adherent cells 
were triturated as described above to ensure that all nonadsorbed virus was 
released. Virus content from supernatants and cell pellets were titrated sepa-
rately to quantify the proportion of virus that had entered adherent cells and 
spheroids.
Immunoblotting
Cell lysates were generated using a modified radioimmunoprecipitation 
assay (RIPA) buffer (50 mmol/l HEPES pH7.4, 150 mmol/l NaCl, 10% glycerol, 
1.5 mmol/l MgCl2, 1 nmol/l ethylene glycol tetraacetic acid, 1 nmol/l sodium 
orthovanadate, 10 mmol/l sodium pyrophosphate, 10 mmol/l sodium 
fluoride, 1% Triton X 100, 1% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate, 1 mmol/l phenylmethylsulfonyl fluoride, 1× protease inhibitor cock-
tail (Roche, Laval, QC)) as described previously.38 Lysates were incubated 
on ice for 20 minutes and vortexed to ensure complete lysis. Lysates from 
day-3 spheroids were triturated using a 26-gauge needle to help facilitate 
lysis. Protein concentrations were then determined by Bradford assay using 
Protein Assay Dye Reagent (BioRad, Mississauga, ON). Thirty micrograms of 
each lysate were run on an 8% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis gel and transferred to a polyvinylidene difluoride membrane 
(Roche, Mississauga, Ontario, Canada). Blots were blocked with 5% skim milk 
in Tris-buffered saline with Tween 20 (TBST; 10 mmol/l Tris-HCl, pH 8.0, 150 
mmol/l NaCl, 0.1% Tween 20). After 1 hour of blocking, blots were incubated 
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on a rocking platform shaker at 4 °C overnight with specific antibodies at 
1:1,000 dilution in bovine serum albumin (BSA)/TBST (anti-LDLR (Abcam, 
ab14056; Cambridge, MA); anti-actin (Sigma)). Blots were washed using TBST 
and incubated with peroxidase-conjugated anti-rabbit IgG (GE Healthcare) 
at 1:10,000 dilution, 5% skim milk/TBST (LDLR) or 5% bovine serum albu-
min/TBST (actin), for 1 hour at room temperature. Blots were washed again 
using TBST followed by incubation with Luminata Forte Western horseradish 
peroxidase substrate (Millipore, Etobicoke, Ontario, Canada) and visualiza-
tion of bands with the ChemiDoc MP System (BioRad, Mississauga, Ontario, 
Canada).
LDL receptor knockdown
SKOV3 cells were seeded in 48-well dishes and transfected the next day 
with siLDLR SMARTPool RNA or the siNT nontargeting control RNA using 
DharmaFECT 1 transfection reagent (Dharmacon). At 48 hours post-transfec-
tion, cells were used for infection experiments (virus entry (MRBV at MOI 0.1) 
and cell viability (MYXV and vvDD at MOI 1; MRBV at MOI 0.1)) as described 
above.
Statistical analysis
Statistical significance was determined by unpaired two-tailed Student’s 
t-test or one-way analysis of variance using GraphPad Prism 6 (GraphPad 
Software, San Diego, CA). Statistical significance was set at P < 0.05.
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